Modulators of hERAP2 discovered by high-throughput screening

Endoplasmic reticulum aminopeptidase 2, ERAP2, is an emerging pharmacological target in cancer immunotherapy and control of autoinflammatory diseases, as it is involved in antigen processing. It has been linked to the risk of development of spondyloarthritis, and it associates with the immune infilt...

Full description

Saved in:
Bibliographic Details
Published in:European journal of medicinal chemistry 2021-02, Vol.211, p.113053, Article 113053
Main Authors: Medve, Laura, Gealageas, Ronan, Lam, Bao Vy, Guillaume, Valentin, Castillo-Aguilera, Omar, Camberlein, Virgyl, Piveteau, Catherine, Rosell, Melissa, Fleau, Charlotte, Warenghem, Sandrine, Charton, Julie, Dumont-Ryckembusch, Julie, Bosc, Damien, Leroux, Florence, van Endert, Peter, Deprez, Benoit, Deprez-Poulain, Rebecca
Format: Article
Language:English
Subjects:
Activators
Aminopeptidases - antagonists & inhibitors
Antigen presentation
Dose-Response Relationship, Drug
Drug Discovery
Enzyme Inhibitors - chemical synthesis
Enzyme Inhibitors - chemistry
Enzyme Inhibitors - pharmacology
Enzymes
Humans
Inhibitors
Life Sciences
Metalloproteases
Models, Molecular
Molecular Structure
Pharmaceutical sciences
Screening
Structure-Activity Relationship
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Endoplasmic reticulum aminopeptidase 2, ERAP2, is an emerging pharmacological target in cancer immunotherapy and control of autoinflammatory diseases, as it is involved in antigen processing. It has been linked to the risk of development of spondyloarthritis, and it associates with the immune infiltration of tumours and strongly predicts the overall survival for patients receiving check-point inhibitor therapy. While some selective inhibitors of its homolog ERAP1 are available, no selective modulator of ERAP2 has been disclosed so far. In order to identify such compounds, we screened an in-house focused library of 1920 compounds designed to target metalloenzymes. Structure-Activity Relationships and docking around two hits led to the discovery of selective inhibitors of ERAP2. Amid those, some bind to yet untapped amino-acids in the S1 pocket. Importantly, we disclose also the first activator of small substrates hydrolysis by ERAP2. Inhibitors and activators identified in this study could serve as useful starting points for optimization. [Display omitted] •Screening of an in-house focused library of metalloenzyme binders provided inhibitors of ERAP2.•Selective ERAP2 inhibitors are described.•Docking revealed original binding modes that are confirmed by SAR.•.►First activator of small substrates hydrolysis by ERAP2 is disclosed.
ISSN:0223-5234
1768-3254
DOI:10.1016/j.ejmech.2020.113053